iSpecimen Achieves Rapid Procurement Milestone for Influenza Research

Rhea-AI Summary

iSpecimen (NASDAQ: ISPC) reported a rapid procurement milestone for influenza research on March 16, 2026, collecting approximately 500 influenza swab samples over several weeks to support a customer project.

The company also maintained supply of cerebrospinal fluid (CSF), and noted rising demand for FFPE and fresh frozen tissue. Customer feedback praised specimen quality and documentation, with one customer indicating intent to credit iSpecimen as the sample source in publications.

News Market Reaction – ISPC

-8.90%

42 alerts

-8.90% News Effect

+16.9% Peak Tracked

-31.2% Trough Tracked

-$271K Valuation Impact

$3M Market Cap

1.5x Rel. Volume

On the day this news was published, ISPC declined 8.90%, reflecting a notable negative market reaction. Argus tracked a peak move of +16.9% during that session. Argus tracked a trough of -31.2% from its starting point during tracking. Our momentum scanner triggered 42 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $271K from the company's valuation, bringing the market cap to $3M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Influenza swab samples: approximately 500 samples Urine specimen shipment: 20 samples Registered resale shares: 101,000,000 shares +5 more

8 metrics

Influenza swab samples approximately 500 samples Collected over several weeks for a customer research project

Urine specimen shipment 20 samples Customer-reviewed urine specimens with positive quality feedback

Registered resale shares 101,000,000 shares Common stock registered on S-3 for Series C conversions

Private placement proceeds $5.5 million Gross proceeds from Dec 2025 Series C private placement

IR services allocation $2,000,000 Portion of private placement proceeds for marketing and IR

Series C stated value $1,000 per share Stated value of each Series C Convertible Preferred share

Conversion discount 85% of prior-day closing price Conversion price formula for Series C Preferred Stock

Nasdaq minimum bid $1.00 per share Bid price compliance requirement with cure deadline of May 18, 2026

Market Reality Check

Price: $0.2215 Vol: Volume 263,638,515 is 15....

high vol

$0.2215 Last Close

Volume Volume 263,638,515 is 15.75x the 20-day average 16,741,821, indicating exceptional activity ahead of this milestone update. high

Technical Price 0.2844 is trading below the 200-day MA at 0.78 and remains far under the 52-week high of 3.18 (52-week low 0.22).

Peers on Argus

While ISPC shows a strong +26.96% move, momentum scanner peers like BIAF (-11.79...

2 Down

While ISPC shows a strong +26.96% move, momentum scanner peers like BIAF (-11.79%) and NOTV (-2.00%) are moving down, and sector momentum text cites peers with a median move of -6.9%, indicating ISPC’s reaction diverges from these peers.

Historical Context

4 past events · Latest: Mar 12 (Positive)

Pattern 4 events

Date	Event	Sentiment	Move	Catalyst
Mar 12	AI platform launch	Positive	+27.0%	Launch of AI-powered Inventory Agent to accelerate biospecimen matching and workflows.
Feb 06	Digital milestone	Positive	-4.4%	Completion of SalesStack Milestone 2 and activation of integrated biospecimen marketplace.
Feb 06	Procurement milestone	Positive	-4.4%	Rapid collection of 500 influenza swab samples and strong customer feedback on specimens.
Dec 30	Private placement	Negative	-13.2%	Approx. $5.5M Series C Convertible Preferred Stock financing with discounted conversion terms.

Pattern Detected

Operational and technology milestones have produced mixed reactions, while financing/dilution-linked events have tended to see negative price moves. The stock has both rallied strongly on product news and sold off on similar positive operational updates.

Recent Company History

Over the past several months, iSpecimen has focused on both platform development and capital structure. On Dec 30, 2025, it announced a private placement of Series C Convertible Preferred Stock for about $5.5 million, which was followed by a -13.15% move. On Feb 6, 2026, it completed SalesStack Milestone 2 and highlighted a rapid procurement milestone, yet shares fell -4.38%. In contrast, the Mar 12, 2026 launch of an AI-powered Inventory Agent coincided with a +26.96% move, showing investors sometimes reward technology enhancements more than operational updates.

Regulatory & Risk Context

Active S-3 Shelf · $5.5 million

Shelf Active

Active S-3 Shelf Registration 2026-01-16

$5.5 million registered capacity

An effective S-3 dated 2026-01-16 registers 101,000,000 common shares for resale tied to Series C preferred conversions. The company does not receive proceeds from these resales and has noted that large resales could put downward pressure on the share price. A related 424B3 was filed on 2026-02-03.

Market Pulse Summary

The stock moved -8.9% in the session following this news. A negative reaction despite operational mi...

Analysis

The stock moved -8.9% in the session following this news. A negative reaction despite operational milestones would fit a pattern where iSpecimen’s positive execution updates, such as SalesStack milestones and procurement achievements, have previously coincided with declines of around 4–13%. In that context, investors might have focused more on structural overhangs, including registered resale of 101,000,000 shares and Nasdaq bid-price compliance risk, rather than on specimen demand and customer feedback.

Key Terms

cerebrospinal fluid (CSF), formalin-fixed paraffin-embedded (FFPE), fresh frozen (FF) tissue, series c convertible preferred stock, +4 more

8 terms

cerebrospinal fluid (CSF) medical

"iSpecimen continues to consistently maintain supply of cerebrospinal fluid (CSF) to support..."

Cerebrospinal fluid (CSF) is a clear liquid that surrounds and cushions the brain and spinal cord, providing protection and helping to remove waste. Although it is a medical term, in a financial context, understanding how resources and support flow within a system can be similar to how CSF circulates and maintains the health of the nervous system. Recognizing such fundamental processes can offer insights into the stability and resilience of broader systems, including financial markets.

formalin-fixed paraffin-embedded (FFPE) medical

"including Formalin-Fixed Paraffin-Embedded (FFPE) and fresh frozen (FF) tissue, reflecting..."

A laboratory method that preserves biological tissue by treating it with a chemical (formalin) to stabilize cells and then embedding the sample in paraffin wax so it can be sliced and stored long-term. For investors, FFPE matters because these preserved samples are the backbone of diagnostic tests, biomarker discovery and clinical validation—think of them as museum specimens that allow companies and regulators to re-examine tissues later for disease markers, test accuracy and drug development decisions.

fresh frozen (FF) tissue medical

"including Formalin-Fixed Paraffin-Embedded (FFPE) and fresh frozen (FF) tissue, reflecting..."

Fresh frozen (FF) tissue is biological tissue that has been frozen quickly after removal to preserve proteins, DNA, RNA and cell structure for laboratory testing. Investors care because FF samples are essential for reliable diagnostic tests, biomarker discovery and drug development; having high-quality FF material or access to it can speed research, reduce regulatory risk and increase the value of medical or biotech programs, much like freezing fresh food preserves nutrients for later use.

series c convertible preferred stock financial

"issuance of 6,875 shares of newly designated Series C Convertible Preferred Stock at $800..."

Series C convertible preferred stock is a class of investment shares issued in a later private financing round that combine safety and upside: they usually pay ahead of ordinary shares if a company pays dividends or is sold, but can be converted into common stock to share in future growth. For investors this acts like a VIP ticket with a safety net—offering priority protection while preserving the option to participate in a successful exit.

conversion price financial

"converts into common stock at a conversion price equal to 85% of the closing price..."

The conversion price is the fixed price at which a convertible security, like a bond or preferred stock, can be exchanged for shares of common stock. It acts like a set rate that determines how many shares an investor can receive if they choose to convert their investment. This helps investors understand the value and potential benefits of converting their securities into company shares.

floor price financial

"makes both the Conversion Price and the Floor Price subject to proportionate adjustment..."

The floor price is the minimum price at which a security, asset, or offering will be sold or accepted, acting like a seller’s “bottom line” or a reserve in an auction. For investors it matters because it sets a visible downside limit and can influence trading, valuation, and expectations of risk—like knowing there’s a safety net that a sale won’t go below a set level.

reverse stock split financial

"if there is any reverse stock split, share combination or similar transaction that reduces..."

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

nasdaq capital market regulatory

"Its stock trades on the Nasdaq Capital Market under the symbol ISPC..."

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

AI-generated analysis. Not financial advice.

Woburn, Massachusetts--(Newsfile Corp. - March 16, 2026) - iSpecimen Inc. (NASDAQ: ISPC) (the "Company"), a leading provider of human biospecimens for research, is proud to announce recent milestones that demonstrate the responsiveness and capabilities of its site network. Over the past several months, iSpecimen has been actively supporting customer research by sourcing high-quality respiratory samples, with a particular focus on influenza. Most recently, iSpecimen successfully collected approximately 500 influenza swab samples over a period of several weeks to support a customer research project—demonstrating its ability to respond quickly to time-sensitive research needs. The rapid turnaround and quality of the specimens have led to continued engagement with the customer in future respiratory sampling needs.

In addition to respiratory specimens, iSpecimen continues to consistently maintain supply of cerebrospinal fluid (CSF) to support ongoing customer studies. The company is also experiencing increased interest from clients seeking support across a broader range of specimen types, including Formalin-Fixed Paraffin-Embedded (FFPE) and fresh frozen (FF) tissue, reflecting growing demand for reliable and diverse biospecimen sourcing.

Customer feedback continues to reinforce iSpecimen's commitment to quality and transparency. One recent customer commented:

"We were very excited upon receiving the urine specimens from iSpecimen and have begun to review all the information we received about the 20 samples. I must say that we are very impressed with their quality, and their extensive documentation."

The customer also indicated their intent to mention iSpecimen as the sample source in public discussions and publications, underscoring confidence in both specimen quality and accompanying documentation.

These accomplishments highlight iSpecimen's ongoing commitment to providing timely access to well-documented biospecimens that support critical research and scientific advancement.

About iSpecimen

iSpecimen is a technology-driven marketplace that connects life science researchers with a global network of biospecimen suppliers. The Company's platform simplifies and accelerates access to human biological samples, enabling researchers to find the specimens they need to advance medical science and improve patient outcomes.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties, including the risks and uncertainties describes in the Company's filings with the Securities and Exchange Commission (the "SEC"). Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the SEC, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements.

Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, visit www.ispecimen.com

Media Contact
info@ispecimen.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/288639

FAQ

How many influenza swab samples did iSpecimen (ISPC) collect for the March 2026 customer project?

iSpecimen collected approximately 500 influenza swab samples over several weeks for the customer project. According to the company, the rapid procurement demonstrated the site network's responsiveness and supported ongoing engagement for future respiratory sampling needs.

What does the 500-sample procurement mean for iSpecimen's (ISPC) operational capabilities?

The procurement indicates demonstrated rapid-response sourcing capability across the site network. According to the company, this capability enabled timely delivery of high-quality respiratory samples and led to continued customer engagement for future respiratory studies and sampling needs.

Is iSpecimen (ISPC) still supplying cerebrospinal fluid (CSF) for research studies?

Yes, iSpecimen continues to consistently maintain supply of cerebrospinal fluid (CSF) to support ongoing studies. According to the company, CSF availability remains steady while client interest expands to additional specimen types like FFPE and fresh frozen tissue.

What other specimen types is iSpecimen (ISPC) reporting increased interest in during March 2026?

Clients are showing increased interest in FFPE and fresh frozen (FF) tissue beyond respiratory samples. According to the company, demand is growing for diverse biospecimens and reliable sourcing across multiple specimen categories to support varied research needs.

Did customers provide feedback about iSpecimen (ISPC) specimen quality and documentation?

Yes, customers praised specimen quality and the thoroughness of documentation, with one reviewer noting strong quality for urine samples. According to the company, a customer indicated intent to acknowledge iSpecimen as the sample source in public discussions and publications.